11:39 AM EDT, 04/05/2024 (MT Newswires) -- In the coming days/weeks, RBC says it expects the Xifaxan patent litigation ruling by the Appellate Court.

According to analyst Douglas Miehm, the decision is likely to inform and influence BHC's ability to pursue a Bausch + Lomb distribution, and it could unlock material value for BHC and BLCO shareholders. Miehm believes a favourable ruling in the Xifaxan patent litigation would likely position Bausch to pursue a distribution and lead to higher share prices.

"Based on our work, we see ~76% probability that BHC is able to pursue a distribution."

Target raised to US$12 (from US$9). Maintain Sector Perform.

Price: 13.93, Change: +0.30, Percent Change: +2.20